(Q45965429)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23999214%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Haematological cancer: Treatment of smoldering multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23999214%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23999214%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Robert A Kyle

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23999214%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

language of work or name

English

0 references

publication date

3 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23999214%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

8 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23999214%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23999214%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23999214%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

554-555

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23999214%20AND%20SRC:MED&resulttype=core&format=json

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

8 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.160

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.160

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.160

Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.160

Diagnosis of smoldering multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.160

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.160

Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.160

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.160

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.160

Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.160

10.1038/NRCLINONC.2013.160

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23999214%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference